Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
October 30, 2025
Earnings Call Speaker Segments
Morgan Sanford
executiveThanks, operator. Hello, everyone, and good morning. We appreciate you being here as we go over Agios Pharmaceuticals' financial results for the third quarter of 2025 along with our business highlights. The slides for today's call can be found in the Investors section on our site, agios.com. Let's go to the next slide. I want to remind everyone that certain forward-looking statements will be made today. Due to a range of risks and uncertainties and other factors — among them those described in our latest SEC filings and any subsequent documents we file with the SEC — actual events and results might differ materially from what any forward-looking statements express or imply. The agenda for our third quarter earnings call appears on the following slide. On the call with me today are Brian Goff, our Chief Executive Officer; Cecilia Jones, our Chief Financial Officer; Tsveta Milanova, our Chief Commercial Officer; and Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development. Once prepared remarks are done, we'll take questions. So please advance to the next slide, and I'm happy to hand things over to Brian.
Brian Goff
executiveAppreciate that, Morgan. Morning to all of you, and thanks for being here on this call as we walk through the highlights of our third quarter. Starting on the slide that follows this one. Thanks to consistent advancement and a disciplined approach, we see a clear route toward delivering long-term shareholder value. To begin, a number of high-value catalysts are lined up over the next several months, putting PYRUKYND, our foundational PK activator, in position to realize its multi-billion dollar opportunity across PK deficiency, thalassemia, and sickle cell disease. After the FDA recently asked for a REMS program, our PDUFA date for the PYRUKYND thalassemia supplemental NDA has moved to December 7th. We're in active dialogue with the FDA and are using this extra time to deepen our engagement with the thalassemia community and to further sharpen our launch planning. On top of that, we're eager to share top-line results from the RISE UP phase III trial of PYRUKYND in sickle cell disease before the year is out. In the meantime, we keep pushing forward our early and mid-stage pipeline, which consists of our other PK activator tebapivat for lower-risk myelodysplastic syndromes, or MDS, and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. Crucially, our robust balance sheet, holding roughly $1.3 billion in cash and investments, allows us to invest in a disciplined way that both backs our potential U.S. launches and moves our rare disease pipeline ahead. A recap of our third quarter highlights appears on the following slide. During the third quarter, net revenue came in at $12.9 million, highlighting the compelling value proposition of PYRUKYND. In August, we shared news of approval for PYRUKYND in adults with thalassemia in Saudi Arabia, marking our first global regulatory approval for this indication. Earlier this month, we also obtained a positive CHMP opinion recommending PYRUKYND for marketing authorization in Europe for treating adults with thalassemia. Finally, we hit a key R&D priority by finishing enrollment in the phase II-B trial of tebapivat in lower-risk MDS, and we expect top-line data early next year; with ongoing momentum throughout our commercial portfolio and pipeline, our team has shown strong execution and agility, keeping us squarely focused on our mission to deliver transformative medicines for patients; that agility serves as a competitive advantage as we strive to transform the treatment landscape for thalassemia and sickle cell disease. Input from these communities through our recent global engagements underscores the vital need for treatment innovation. Kindly advance to the next slide and I'll hand the call to Cecilia for her commentary on our third quarter performance and full year outlook.
Cecilia Jones
executiveCecilia, thanks, Brian. Please go to the next slide. You can find our financial results for the third quarter of 2025 in the press release that went out this morning, and more information will be available in our 10-Q, which we'll file later today. Now let me spend a moment giving some background and calling out several important items. Net PYRUKYND revenue for the third quarter came in at $12.9 million, which is up 44% from $9 million in the third quarter of 2024, and up 3% from $12.5 million in the second quarter of 2025. The third quarter's net revenue growth shows our continued commercial execution in PKD ahead of a possible U.S. approval for thalassemia. Looking forward, fourth quarter performance will get a lift from one more ordering week than the third quarter had, and we expect PYRUKYND net revenue to keep reflecting our ongoing focus on PK deficiency ahead of potential thalassemia approval in the U.S; on a full-year basis. Because of how strongly our sales force has executed so far, we expect net revenues in 2025 to deliver robust growth relative to 2024, though we acknowledge that this growth is occurring on a fairly small revenue base. Cost of sales for the quarter was $1.7 million. R&D expenses reached $86.8 million, which is $14.3 million higher than the third quarter of 2024; that rise was mainly the result of greater clinical trial costs tied to our PK activation franchise. SG&A expenses came to $41.3 million in the third quarter, up $2.7 million from the prior year, reflecting disciplined investment. Ahead of a possible commercial launch of PYRUKYND in thalassemia, we closed the third quarter with cash, cash equivalents, and marketable securities of roughly $1.3 billion. Please move to the next slide. Our approach to capital allocation, supported by a strong balance sheet, lets us make strategic investments in future growth and in delivering our ongoing pipeline programs. First, we've established a capital-efficient global commercial model, putting priority on investment in potential U.S. launches, since those represent the biggest commercial opportunities. We've struck partnerships with NewBridge Pharmaceuticals in the GCC and Avanzanite Bioscience in Europe, and both are set up as revenue-sharing arrangements that benefit Agios. Over the long term, we will record our share of sales as net revenues. Second, we'll keep investing in our ongoing early and mid-stage clinical programs. Third, we're looking opportunistically for ways to broaden and diversify our pipeline, whether through internal efforts or assets sourced externally. To wrap up, I'm confident our balance sheet will let us keep executing from a position of strength. Please go to the next slide, and I'll hand the call to Tsveta for the quarter's commercial highlights.
Tsveta Milanova
executiveThanks, Cecilia. Could we advance to the following slide? During Q3, PYRUKYND net revenues reached $12.9 million, which was a 3% rise from the prior quarter, again showing how well our commercial team has executed. As of now, 262 patients have finished prescription enrollment forms, with 14 of those coming in Q3, which marks a 6% gain. On a sequential basis, that has resulted in 149 patients who are currently receiving therapy, a 5% increase over Q2. These figures highlight how robust our commercial model is and the base we're creating for growth ahead. We're in a solid position to carry out possible U.S. launches for thalassemia and sickle cell disease. Kindly go to the next slide. Now let's discuss thalassemia and how we're commercializing PYRUKYND around the world. After our PDUFA goal date was extended by 3 months to December 7th, we still feel confident about our capacity to achieve a successful launch, assuming regulatory approval comes through; that confidence has only grown thanks to our recent talks with physicians, patients, and advocacy organizations, which I'll get into shortly. Beyond the U.S., we've put in place a capital-efficient worldwide commercialization approach via alliances with NewBridge Pharmaceuticals in the GCC and Avanzanite Bioscience in Europe. Through these alliances, we keep all rights to PYRUKYND and also safeguard our capital investment for U.S. launches. In August, we shared that the SFDA approved PYRUKYND for treating adult thalassemia patients in Saudi Arabia, which is our first approval for thalassemia anywhere in the world. Launch efforts are now active in Saudi . Our partner NewBridge is offering early patient access case by case, and there's a chance to broaden that access once a national procurement agreement is secured within the next couple of years. When it comes to Europe, we expect a regulatory decision from the European Commission in early 2026 after the favorable CHMP recommendation, and we're working closely with our partner Avanzanite Bioscience to sharpen our launch approach. Kindly go to the next slide; within the U.S., roughly 6,000 adults have a diagnosed case of thalassemia. It's crucial to keep in mind that thalassemia is viewed as a spectrum of disease rather than one phenotype. Patients span from those needing routine transfusions to those who aren't transfusion dependent yet still deal with severe fatigue and significant complications as time goes on. Treatment aims across the disease focus on three main to address patients, chronic anemia and hemolysis, boost their quality of life, and lower the chance of comorbidities that primary or secondary iron overload may bring about. These patients receive care at both academic centers and community hematology practices, and we're set up to handle both. During the last year, we've profiled and ranked accounts across various settings. We also reached out to prescribers where patients get managed and provided disease education to them. After we announced the extension of our PDUFA goal date, we've seized the chance to keep up our engagement with the thalassemia community. Via these continuing interactions, stakeholders repeatedly acknowledge the obvious and strong potential of PYRUKYND. People championing this cause, along with doctors treating these individuals, keep highlighting just how substantial the unmet needs are for those living with thalassemia, and they repeatedly underscore how pressing it is to bring forward innovative options such as PYRUKYND. On top of that, it's now evident that physicians are quite familiar with and experienced in using REMS, whether they work in academic or community environments, and they don't see a possible REMS program as something that would stop them from prescribing. The rare disease framework we've already built provides a distinct edge when it comes to introducing PYRUKYND for thalassemia. Thanks to our high-touch patient services and a single specialty pharmacy model, we're positioned well to move quickly and stay compliant inside a REMS structure. Our team is prepared, and we're eager for a possible thalassemia approval before the year ends. We feel strongly about our capacity to pull off a successful launch, and with that said, please advance to the following slide, and I'll pass the call to Sarah, who will walk through the quarter's key R&D highlights.
Sarah Gheuens
executiveThanks, Tsveta. Let's go to the next slide. During Q3, we kept up strong momentum throughout our pipeline. At the start of August, we shared news that PYRUKYND had won approval in Saudi Arabia for adults who have thalassemia, and earlier this month we got a positive CHMP opinion backing marketing authorization for PYRUKYND in adults, in Europe, to treat anemia tied to transfusion-dependent and non-transfusion-dependent alpha or beta thalassemia, and we're expecting a final regulatory decision by early next year. On top of that, our reviews are still underway in the United Arab Emirates and in the U.S., where we keep moving toward our new PDUFA goal date of December 7th. Outside of PYRUKYND, we were happy to report that enrollment has finished in the phase II-B study of tebapivat for treating low-risk MDS. Tebapivat, our more potent PK activator, could become the first oral therapy addressing anemia caused by ineffective erythropoiesis in patients who have low-risk MDS. I'll say more about this potential opportunity in a bit. Please go to the next slide. With the anticipated top-line results from the phase III RISE UP trial getting close, I wanted to briefly call attention to the substantial need within this community, along with our potential to provide a disease-modifying novel treatment using PYRUKYND. Roughly 100,000 adults and children in the United States have a sickle cell disease diagnosis, and the number globally is considerably bigger. Sickle cell disease is still profoundly underserved. The absence of suitable treatment options fuels a high mortality rate that has actually gotten worse, with U.S. life expectancy sitting in the late 30s. Highlighting a major opportunity for therapeutic innovation, PYRUKYND could be a first-in-class oral therapy for sickle cell disease that targets both hemolysis and vaso-occlusion via a unique PK activation mechanism of action, activating both PKR and PKM2 isoforms, lowering 2,3-DPG, restricting hemoglobin S polymerization, and boosting ATP to support red blood cell health. Please go to the next slide. Informed by extensive engagement with the sickle cell community, we built the phase III RISE UP trial to match clinical needs, positioning PYRUKYND to potentially transform the treatment landscape for sickle cell disease. One of the two primary endpoints looks at hemoglobin increase, which tackles chronic anemia and may thereby cut organ damage and improve how patients feel and function. Our other primary endpoint assesses the reduction in analyzed rate of sickle cell pain crises, which are tied to organ dysfunction, early mortality, and a lower quality of life for many patients. Importantly, one of our key secondary endpoints will look into potential improvement in fatigue, an overlooked symptom; indeed, chronic fatigue among sickle cell disease patients has been shown to be comparable to fatigue felt by patients with other debilitating diseases such as cancer and cystic fibrosis. In the trial, we'll measure the improvement from baseline on the PROMIS Fatigue 13a scale, a validated measure of fatigue for this population. We expect to report top-line findings from the phase III RISE UP study before this year is over. Kindly advance to the following slide, where we provide a high-level overview of how the trial was designed and our statistical plan. As a reminder, because there are two primary endpoints in this trial, a positive result is achieved when statistical significance is reached on either one of them. Our pre-specified statistical testing strategy permits evaluation of the key secondary endpoints provided at least one primary endpoint has been met, which keeps open the chance to demonstrate benefit on other important features of the disease, such as fatigue. Our confidence remains strong that PYRUKYND could become a transformative therapy for sickle cell patients — an underserved and underrepresented population facing significant unmet needs. Next slide, please. I want to briefly highlight our second pyruvate kinase activator, tebapivat, which is more potent and is under investigation in ongoing phase II trials for two rare disease indications: lower-risk myelodysplastic syndromes and sickle cell disease. Lower-risk MDS represents roughly 70% of all myelodysplastic syndromes. For most patients, symptomatic anemia is the main concern. As a result, the primary treatment goal is improving quality of life through management of the underlying anemia caused by ineffective erythropoiesis. Reduced glycolytic activity has been observed in MDS patients, who may display lower PK activity along with an abnormal pyruvate kinase hexokinase enzymatic ratio. Tebapivat is engineered to correct RBC metabolism by boosting ATP production and normalizing the PKHK ratio. Currently, few treatment options exist for low-risk MDS, and we believe tebapivat could become the first oral medicine to address anemia resulting from ineffective erythropoiesis. We finished the phase II portion in November 2023 and moved on to the phase II-B portion, which assesses three higher doses that had been evaluated in the phase II-A portion. This trial will study 10 mg, 50 mg, and 20 mg doses of tebapivat taken daily against placebo across 24 weeks. Today we announced that enrollment is complete, and we still anticipate top-line data in early 2026. We are also studying tebapivat as a treatment for sickle cell disease. Enrollment continues in the phase II trial, and we look forward to sharing updates over the coming months. Please move to the next slide; we continue to advance our early-stage rare disease pipeline with AG-181, an oral PAH stabilizer intended to treat phenylketonuria, and AG-236, a siRNA that selectively targets TMPRSS6 for treating polycythemia vera. Our first early-stage program is AG-181 for treating PKU. In the U.S., between 15,000 and 20,000 patients are diagnosed with phenylketonuria, and symptoms among these patients can range from mild to severe. Treatment options available today have shown limited efficacy or significant safety issues, which leaves patients with a treatment gap and restricted to phenylalanine-restricted diets, thereby substantially affecting a patient's quality of life. Right now, our phase I multiple ascending dose study in healthy volunteers is still underway, and we're eager to share updates on that trial down the road. AG-236 is what we call our second early-stage program, and it's aimed at treating polycythemia vera — a rare blood disease that impacts around 100,000 patients across the U.S. With PV, the body makes too many red blood cells, which raises blood volume and viscosity, and that can lead to thrombosis, cardiovascular events, or even death. When it comes to available therapies, the choices are basically phlebotomy, hydroxyurea, and other cytoreductive treatments. Even so, for patients whose disease is more severe, those medications fail to get hematocrit under adequate control. In our view, AG-236 could meet this lingering unmet need, offering a potentially better safety and efficacy profile along with dosing that's needed less often. During the prior quarter, we obtained IND clearance and gave the first dose to the initial subject in the phase I trial among healthy volunteers, and we're eager to share updates as that trial moves forward. So with that, let's go to the next slide, and I'll turn the call back over to Brian for closing remarks.
Brian Goff
executiveAppreciate that, Sarah. Let's bring up the following slide. During Q3, we made substantial strides on the R&D goals we set for 2025, demonstrating yet again that we can move quickly and get things done. As we look to the future, Q4 brings some thrilling milestones. We're refining our launch preparations ahead of the updated December 7th PDUFA target action date for PYRUKYND in thalassemia, and by the close of the year, we anticipate sharing top line data from the phase III RISE UP study of PYRUKYND in sickle cell disease. Kindly advance to the subsequent slide. Our core strengths are intact. With an experienced leadership group that has demonstrated success over time, we keep pushing our pipeline forward and generating real impact for the rare disease communities we work with — communities whose perspectives inform our efforts and are essential to what we achieve; we're functioning from a place of strength, supported by a balance sheet that doesn't just underwrite our anticipated U.S. launches and the progression of current clinical programs, but additionally allows us to seek out strategic business development possibilities to broaden and diversify our pipeline further and make certain we can build long-term shareholder value. Prior to transitioning to Q&A, I'd like to briefly acknowledge the ongoing commitment of our team members, whose unwavering focus and dedication keep producing meaningful impact for patients living with rare diseases. Their efforts, alongside the voices of the communities we serve, form the bedrock of our mission. Going forward, we stay steadfast in chasing transformative medicines, driving innovation forward with the goal of generating long-term value for patients and shareholders alike; so with that, I'd like to invite questions now. Operator, please open the line.
Eric Schmidt
analystThanks for giving me the chance to ask something. So, first, regarding the thalassemia review — it's been roughly 2 months since the PDUFA extension came through. Do you have a clearer picture yet of the kind of REMS program the FDA wants here? I realize there's a range, with some REMS programs being more burdensome and others less so. Then my second question, a follow-up. I believe both Cecilia and Brian said the company is actively seeking external assets. At this point, what sort of BD would make sense for the company? Would you hold off on a transaction until the sickle cell readout?
Brian Goff
executiveThanks. Good morning, Eric. I appreciate the question. I'll have Sarah handle the first one, and then I can take the external pursuit question. Sarah, over to you.
Sarah Gheuens
executiveAbsolutely, Eric — appreciate the question. When it comes to the REMS and the label, the review, as you're aware, is still underway, and our PDUFA date has been extended to December 7th. Following our standard practice, we don't discuss specifics of the REMS or the label. That said, you're right that REMS programs take a variety of shapes. Since the REMS was requested over hepatocellular injury, as you know, it's reasonable to expect that monitoring will be part of it, along with some type of education.
Brian Goff
executiveEric, regarding your second question, when it comes to growing our pipeline further, what we chase isn't really linked to any specific thing. The effort our team puts into searching broadly and consistently evaluating many different possibilities makes me genuinely proud. This applies to outside sources, but also to what we develop ourselves, in-house, checking whether additional indications, say, are worth going after. Generally speaking, that isn't attached to anything in particular. Naturally, rare diseases are where we excel. We seek out treatments capable of delivering transformative impact for patients, with chances to reduce risk early when we're discussing assets in earlier stages. Another possibility, I'd add, would be finding something that need not be first in class. Our standard is always best in class, something we take great pride in given our existing organic pipeline. That effort keeps going, and as I mentioned, I'm truly proud of what our team can do, whether through internal possibilities or ones from outside.
Eric Schmidt
analystThank you, and best of luck with those readouts that are coming up.
Brian Goff
executiveI really appreciate that. It was a quarter full of excitement.
Alec Stranahan
analystHi everyone, we appreciate you fielding our questions. We have just a few. It has been fascinating to observe the way various regions have handled the liver injury risk associated with mitapivat and thalassemia. Could you perhaps remind us of the liver monitoring obligations that have been imposed thus far in Saudi Arabia, and possibly in Europe should approval happen there too. Might that shift based on the U.S. label? Then maybe a second item as a follow-up. I'm wondering how this monitoring obligation might be altering your commercial strategy across those regions. Thanks.
Brian Goff
executiveYes, thank you, Alec. Once more, Sarah can begin regarding the labeling to date, and let me jump ahead by noting the label we currently possess, naturally as of now is only in Saudi Arabia, and Sarah is able to speak to that. We remain in the process with FDA, and in Europe there's a CHMP positive opinion, yet we are still waiting for that review to conclude over the next couple of months, with an expectation of that happening by early next year. I'll ask Tsveta to speak about the effect of a few of those scenarios. Sarah, would you like to begin?
Sarah Gheuens
executiveAbsolutely. About the label — yes, that’s right. When it comes to Saudi Arabia, it matches what we put forward: monitoring once every month during the initial 6 months. At this time, that label isn’t available in the European Union. We’re genuinely glad to have gotten a positive opinion from the CHMP, which in their view validates the benefit-risk profile we observed. Naturally, the label becomes final only once the EC decision is issued, so specifics will be accessible at that moment. Brian touched on this already, though the U.S. review continues.
Brian Goff
executiveThanks, Sarah. Tsveta, comments on potential impact of REMS.
Tsveta Milanova
executiveSure, it's widely recognized that thalassemia patients overall have extremely limited therapeutic choices, and when it comes to those who are non-transfusion dependent alongside those who are transfusion dependent, our confidence stays firmly rooted in the compelling benefit-risk profile that PYRUKYND offers this population; that view has been echoed and affirmed by every stakeholder group we engage with, including each of the clinicians I've recently spoken with out in the field. Following the news about REMS tied to the possible U.S. label, I can share that our team stands ready for the launch. We're using this extra time to keep building relationships within the community and to advance disease education. Regarding REMS here in the U.S., our expectation is that it won't create an obstacle to prescribing or affect our commercial opportunity, since we're aware that academic hematology and oncology practices, as well as community ones, already have familiarity with REMS. When I spoke with both academic and community prescribers, they verified this for me, and our team continues to verify it in the field every single day.
Alec Stranahan
analystExcellent. I appreciate the additional detail, and I can't wait for December.
Brian Goff
executiveYes, likewise. Thanks.
Brian Goff
executiveMuch appreciated. I believe we'll proceed with the same sequence for entering these topics. Sarah, you can kick things off regarding tebapivat and our perspective on what's possible in low-risk MDS—an area with substantial unmet need, just like the pattern across every disease we're going after, where available therapies are quite restricted. Tsveta, you can speak to Avanzanite and likely also include a few remarks on NewBridge; we have two highly valued collaborators beyond the U.S. Sarah, would you like to begin?
Sarah Gheuens
executiveCertainly. I appreciate the question. When it comes to the encouraging results in lower-risk MDS, it makes us quite happy that today we could share news about enrollment completing for our phase II-B study. Additional findings from our program are expected early next year. Naturally, as we review the data this program produces, we will factor in the broader ecosystem surrounding us. The key point, in my view, is what Brian said a moment ago. This patient group faces an enormous unmet need, particularly since the aim for these individuals is increasingly centered on quality of life as well. For PK activators, as you're aware, quality of life has formed a significant part of their benefit profile. That's something we were certainly aspiring to provide.
Brian Goff
executiveOkay, thank you Sarah and Tsveta. Turning now to Avanzanite — and given that you've recently been abroad in Saudi Arabia too, perhaps you could also speak to NewBridge when it comes to getting our partners ready.
Tsveta Milanova
executiveCertainly. To begin with Avanzanite, we're quite enthusiastic about the possibility of an EC decision and approval for PYRUKYND in thalassemia across Europe arriving in early 2025; together with the Avanzanite team, we're collaborating intensively to sharpen our European approach. One key point is that within Europe, once a regulatory decision and approval occur, every country must go through its own pricing and reimbursement procedure. Right now, alongside Avanzanite, we're evaluating market opportunities and determining which markets to prioritize for pricing and reimbursement submissions. That pricing and reimbursement procedure across European nations may require 12 to 18 months. Bear in mind that following the EC decision announcement, we wouldn't experience any immediate commercial effect from an approval in Europe. Avanzanite was chosen as our partner because of their exceptional rare disease capabilities and expertise, along with strengths in pricing and market access. We're eager to keep collaborating with them so patients in Europe can gain access. As Brian noted, I actually got to spend time with the team in Saudi for the August SFDA approval. Once again, a very comparable team exists here in Saudi Arabia. We keep hearing about the significant unmet need among thalassemia patients, along with considerable enthusiasm regarding PYRUKYND's benefit-risk profile and the value it may deliver to that community. As a reminder, within Saudi Arabia, the post-approval pathway begins with one-on-one physician requests for individual patients seeking PYRUKYND during the early patient access and market access phase. Reaching a national procurement agreement, which would broaden access and reveal the commercial opportunity there, will require roughly a couple of years.
Brian Goff
executiveGood. Thank you. That makes sense. Thank you for answering our questions. You're welcome.
Marc Frahm
analystMarc, thanks for the questions. First, regarding the liver events — as you keep administering doses and tracking patients over extended periods, could you share whether any further events have shown up in the PKR studies? And if so, do they still match the earlier profile, meaning they happen within 6 months and, crucially, the patient goes back to baseline once they cease MIT? Then on the business side, I know it will take considerable time to handle access individually and reach revenue for those patients, not to mention working out reimbursement. Could you say something about what demand you are already observing in the Gulf as that process gets underway?
Brian Goff
executiveSure, Marc, thank you. Sarah, why don't you begin with Mark's question about hepatocellular injury and whether more cases have fit the pattern we saw in thalassemia? After that, Tsveta can discuss what I'd call the green shoots of demand we've seen so far.
Sarah Gheuens
executiveYes. As for what we saw in the thalassemia program, which let us establish the hepatocellular injury risk specifically for thalassemia, our approach to evaluating that risk is unchanged. The safety profile is exactly what it was when we announced this hepatocellular injury risk. Nothing seen throughout the program gives us reason to revise the safety profile as we presently understand it.
Brian Goff
executiveAll right, thank you, Sarah. Tsveta.
Tsveta Milanova
executiveYes, ma'am. In fact, this week I was able to sit down with a number of important customers at several of the largest hospitals in Saudi Arabia. As I mentioned, we clearly are picking up on enthusiasm for what PYRUKYND offers, along with a wish to use it with specific patients and build familiarity with the product right at the start in that nation. That pathway is quite onerous; in truth, it stretches across months, starting with a prescription and request for one patient and running through hospital-level sign-off and locking in the budget. Our expectation is that this will move slowly — slowly but steadily. As approvals come through for those single-patient requests, the hands-on knowledge keeps growing stronger. There is no doubt that the community's interest exists and runs high. It is simply that the timeline in that country requires patience.
Brian Goff
executiveMarc, something I'd like to mention is that Saudi Arabia stands out in a particular way: the frequency there differs substantially from what's observed in the U.S. When you look at it per person, it's roughly 8 to 9x more prevalent; definitely on the more common end of things, and most individuals, most doctors surely possess solid practical familiarity with thalassemia; even so, what ties everything together regardless of where you look is really driven by how few therapeutic choices exist and by our ongoing need to keep raising awareness, especially regarding the daily toll that non-transfusion dependent thalassemia patients endure since they deal with ongoing hemolysis along with every consequence further down the line from it; we're contributing our efforts to ensure that this stays front of mind for clinicians as they consider what tebapivat and PYRUKYND might be able to deliver. That aspect isn't tied to any particular location; it holds true in every market globally.
Marc Frahm
analystOkay, thank you.
Brian Goff
executiveYou're welcome.
Tessa Romero
analystHello Brian and the rest of the team, we really appreciate you fielding our question. Regarding the phase III part of RISE UP, has the final patient completed the study at this point, and what should we keep in mind about the sequence of steps and the expected timing before you report top line? I have one more question after that.
Brian Goff
executiveAlright, I'll let Sarah weigh in here. Let me just note that we won't get any more specific than our current guidance on the timing for the RISE UP readout that everyone is waiting for so eagerly. Saying we remain on schedule for those results by the close of the year is as precise as we'll be. Sarah, I don't know whether you'd like to add anything further regarding where things stand in that process.
Sarah Gheuens
executiveNot exactly — that felt more like your recap, Brian. We won't speak to how any specific patient is doing. Even so, we remain on schedule to have the top line data before the year is out. Several phase III clinical trials have already been delivered, consistent with our milestone. At this stage, we operate like a well-oiled machine when it comes to moving from database lock all the way to top line results.
Tessa Romero
analystOkay.
Brian Goff
executiveTess, let me jump in here if I may — I'm genuinely happy about how well the team keeps executing, since obviously quite a few things are in motion at once. At the same time, we're getting ready for a launch. Tsveta has already spoken to you, and Sarah plus the team are handling the labeling work tied to the PDUFA date coming up for thalassemia on December 7th, and on top of that, preparations are underway for a RISE UP data readout. This group is truly performing, and the operational work makes me very pleased.
Tessa Romero
analystAll right, so we still don't know from you whether that top line readout lands ahead of your PDUFA date or behind it.
Brian Goff
executiveThat's a really good one to come back with. My answer stays the same: by year end.
Tessa Romero
analystOkay, thanks so much, guys.
Brian Goff
executiveYou're welcome.
Lydia Erdman
analystMorning, everyone. Lydia here, filling in for Salveen. We appreciate you taking our question. Perhaps I'll ask one more. Regarding the REMS program, are you expecting those requirements to end up applying throughout the label for PKD and sickle cell too? Has any physician input come in about how that could affect adoption, especially in sickle cell, where certain treatment sites may not be seeing PKD and thalassemia patients either? Many thanks.
Brian Goff
executiveLydia, I believe I'll jump in here and note, first, that the REMS request was specifically for thalassemia; that point matters. As for whatever possible result or effect in sickle cell disease, the key move is exactly what we were just talking about, which is reaching the point of the RISE UP phase III data. That's the critical next step. After that, we'll have better guidance regarding the benefit risk profile.
Lydia Erdman
analystHelpful. Thank you.
Brian Goff
executiveYou're welcome.
Brian Goff
executiveI appreciate everyone being here for today's morning call. As you've already observed, and just as I noted, we have achieved quite a few of our objectives over this year. Two of the turning points we've been looking forward to most are coming up before the year finishes. It's easy to understand that this marks a really thrilling period at Agios. We genuinely hold the belief that we're positioned to bring forward game-changing new treatments for patients while generating substantial value for shareholders over the long term. Thanks once more, and we hope to talk with you again before long.
Operator
operatorThat brings us to the end of today's conference call. We appreciate everyone joining in, and at this point you're free to disconnect. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.